Continuous hemodiafiltration with cytokine-adsorbing hemofilter in the treatment of severe sepsis and septic shock

Contributions to Nephrology

Volumn 156, Issue , 2007, Pages 365-370

  Hirasawa, Hiroyuki ^a   Oda, Shigeto ^a,c   Matsuda, Kenichi ^b  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

^c NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HLA DR ANTIGEN; POLY(METHYL METHACRYLATE);

APOPTOSIS; ARTICLE; BLOOD; BLOOD PRESSURE; GENETIC POLYMORPHISM; GENETICS; HEMODIAFILTRATION; HUMAN; INSTRUMENTATION; ISOLATION AND PURIFICATION; METHODOLOGY; NEUTROPHIL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SEPSIS; SEPTIC SHOCK;

APOPTOSIS; BLOOD PRESSURE; CYTOKINES; HEMODIAFILTRATION; HLA-DR ANTIGENS; HUMANS; NEUTROPHILS; POLYMETHYL METHACRYLATE; POLYMORPHISM, GENETIC; SEPSIS; SHOCK, SEPTIC;

EID: 34247567529     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/0000102127     Document Type: Article

References (21)

1. Tetta C, Bellomo R, D'Intini V, et al: Do circulating cytokines really matter in sepsis? Kidney Int 2003;63(suppl):S69-S71.
2. Wang H, Czura CJ, Tracey KJ: Lipid unites disparate syndromes of sepsis. Nat Med 2004;10:124-125.
3. Lotze MT, Tracey KJ: High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-342.
4. Kox WJ, Volk T, Kox SN, et al: Immunomodulatory therapies in sepsis. Intensive Care Med 2000;26:S124-S128.
5. Schetz M, Ferdinande P, van den Berghe G, et al: Removal of pro-inflammatory cytokines with renal replacement therapy: sense or nonsense? Intensive Care Med 1995;21:169-176.
6. Heering P, Grabensee B, Brause M: Cytokine removal in septic patients with continuous venovenous hemofiltration. Kidney Blood Press Res 2003;26:128-134.
7. Ronco C, Tetta C, Mariano F, et al: Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 2003;27:792-801.
8. Cole L, Bellomo R, Journois D, et al: High-volume haemofiltration in human septic shock. Intensive Care Med 2001;27:978-986.
9. Cornejo R, Downey P, Castro R, et al: High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med 2006;32:713-722.
10. Matsuda K, Hirasawa H, Oda S, et al: Current topics on cytokine removal technologies. Ther Apher 2001;5:306-314.
11. Nakada T, Hirasawa H, Oda S, et al: Blood purification for hypercytokinemia. Transfusion Apher Sci 2006;35:253-264.
12. Hirasawa H, Oda S, Matsuda K, et al: Clinical aspect of hypercytokinemia-induced pathophysiology in critical care; in Ogawa M, Yamamoto T, Hirota M (eds): The Biological Response to Planned and Unplanned Injuries: Cellular, Molecular and Genetic Aspects. Excerpta Medica. Int Congr Ser 1255. Amsterdam, Elsevier, 2003, pp 39-40.
13. Oda S, Hirasawa H, Shiga H, et al: Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome/sepsis. Cytokine 2005;29:169-175.
14. Hirasawa H, Baue AE: Blood purification therapy to prevent or treat MOF; in Baue AE, Faist E, Fry DE (eds): Multiple Organ Failure: Pathophysiology, Prevention, and Therapy. New York, Springer, 2000, pp 501-504.
15. Hirasawa H, Oda S, Shiga H, et al: Endotoxin adsorption or hemodiafiltration in the treatment of multiple organ failure. Curr Opin Crit Care 2000;6:421-425.
16. Oda S, Hirasawa H, Shiga H, et al: Management of intra-abdominal hypertension in patients with severe acute pancreatitis with continuous hemodiafiltration using a polymethyl methacrylate membrane hemofilter (PMMA-CHDF). Ther Apher Dial 2005;9:355-361.
17. Hirano T, Hirasawa H, Oda S, et al: Modulation of polymorphonuclear leukocyte apoptosis in the critically ill by removal of cytokines with continuous hemodiafiltration. Blood Purif 2004;22:188-197.
18. Ma P, Chen D, Pan J, et al: Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Crit Care Med 2002;30:1046-1050.
19. Watanabe E, Hirasawa H, Oda S, et al: Extremely high interleukin-6 blood levels and outcome in the critically ill are associated with tumor necrosis factor- and interleukin-1-related gene polymorphisms. Crit Care Med 2005;33:89-97.
20. Nakada K, Hirasawa H, Oda S, et al: Influence of toll-like receptor 4, CD14, tumor necrosis factor, and interleukin-10 gene polymorphism on clinical outcome in Japanese critically ill patients. J Surg Res 2005;129:322-328.
21. Watanabe E, Hirasawa H, Oda S, et al: Cytokine-related genotypic differences in peak interleukin-6 blood levels of patients with SIRS and septic complications. J Trauma 2005;59:1181-1190.